Effect of intravenous Ascorbic Acid on reducing ferritin in Hemodialysis Patients
Not Applicable
- Conditions
- End-stage renal disease.End-stage renal disease
- Registration Number
- IRCT138904263325N3
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
receiving hemodialysis therapy for at least 6 months, administered EPO for 6 months or longer at a dose of 80-360 U/kg/wk or greater, rolling 3-month average Hb level of 11.0 g/dL or less (110 g/L), ferritin level greater than 500 ng/Ml, transferrin saturation (TSAT) of 20% or less and administered maintenance intravenous iron (25-100 mg/week)
Exclusion criteria: bone marrow malignancy, myelodysplastic syndrome, evidence of chronic infection, hemochromatosis, hemoglobinopathies, evidence of significant bleeding (decrease in Hb level = 2 g/dL during the past 3 months, mean corpuscular volume greater than 100 fL, biointact parathyroid hormone (bio-PTH) level greater than 500 pg/mL (ng/L)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ferritin. Timepoint: begining of each phase and after 3 months. Method of measurement: laboratory techniques.;Hemoglobin. Timepoint: beginning of each phase and each months (0-1-2-3). Method of measurement: laboratory techniques.
- Secondary Outcome Measures
Name Time Method Serum Iron. Timepoint: at the beginning of study and after 3 months. Method of measurement: laboratory techniques.;TIBC. Timepoint: at the beginning of study and after 3 months. Method of measurement: laboratory techniques.